Your browser doesn't support javascript.
loading
Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8.
Walle, Thomas; Kraske, Joscha A; Liao, Boyu; Lenoir, Bénédicte; Timke, Carmen; von Bohlen Und Halbach, Emilia; Tran, Florian; Griebel, Paul; Albrecht, Dorothee; Ahmed, Azaz; Suarez-Carmona, Meggy; Jiménez-Sánchez, Alejandro; Beikert, Tizian; Tietz-Dahlfuß, Alexandra; Menevse, Ayse Nur; Schmidt, Gabriele; Brom, Manuela; Pahl, Jens H W; Antonopoulos, Wiebke; Miller, Matthias; Perez, Ramon Lopez; Bestvater, Felix; Giese, Nathalia A; Beckhove, Philipp; Rosenstiel, Philip; Jäger, Dirk; Strobel, Oliver; Pe'er, Dana; Halama, Niels; Debus, Jürgen; Cerwenka, Adelheid; Huber, Peter E.
Afiliación
  • Walle T; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kraske JA; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Liao B; Department of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany.
  • Lenoir B; German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Timke C; Department of Immunobiochemistry and MI3, Mannheim Institute for Innate Immunoscience, Heidelberg University, Medical Faculty Mannheim, Mannheim, Germany.
  • von Bohlen Und Halbach E; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tran F; Department of Radiooncology and Radiotherapy, University Hospital Heidelberg, Heidelberg, Germany.
  • Griebel P; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Albrecht D; Department of Radiooncology and Radiotherapy, University Hospital Heidelberg, Heidelberg, Germany.
  • Ahmed A; Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany.
  • Suarez-Carmona M; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jiménez-Sánchez A; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Beikert T; Department of Radiation Oncology, St. Franziskus Hospital, Flensburg, Germany.
  • Tietz-Dahlfuß A; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Menevse AN; Department of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany.
  • Schmidt G; Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany.
  • Brom M; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Pahl JHW; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Antonopoulos W; Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Miller M; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Perez RL; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bestvater F; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Giese NA; Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany.
  • Beckhove P; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Rosenstiel P; Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany.
  • Jäger D; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Strobel O; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pe'er D; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Halama N; Department of Radiooncology and Radiotherapy, University Hospital Heidelberg, Heidelberg, Germany.
  • Debus J; Department of Molecular and Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cerwenka A; Leibniz Institute for Immunotherapy, Division of Interventional Immunology, Regensburg, Germany.
  • Huber PE; Core Facility Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sci Adv ; 8(12): eabh4050, 2022 03 25.
Article en En | MEDLINE | ID: mdl-35319989
ABSTRACT
Radiotherapy is a mainstay cancer therapy whose antitumor effects partially depend on T cell responses. However, the role of Natural Killer (NK) cells in radiotherapy remains unclear. Here, using a reverse translational approach, we show a central role of NK cells in the radiation-induced immune response involving a CXCL8/IL-8-dependent mechanism. In a randomized controlled pancreatic cancer trial, CXCL8 increased under radiotherapy, and NK cell positively correlated with prolonged overall survival. Accordingly, NK cells preferentially infiltrated irradiated pancreatic tumors and exhibited CD56dim-like cytotoxic transcriptomic states. In experimental models, NF-κB and mTOR orchestrated radiation-induced CXCL8 secretion from tumor cells with senescence features causing directional migration of CD56dim NK cells, thus linking senescence-associated CXCL8 release to innate immune surveillance of human tumors. Moreover, combined high-dose radiotherapy and adoptive NK cell transfer improved tumor control over monotherapies in xenografted mice, suggesting NK cells combined with radiotherapy as a rational cancer treatment strategy.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Interleucina-8 / Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Sci Adv Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células Asesinas Naturales / Interleucina-8 / Neoplasias Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Sci Adv Año: 2022 Tipo del documento: Article